SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithKline (GSK) would cut retail prices in India to cater to the lower-income segment besides pumping in Rs 430 crore to develop vaccines from its local facilities, according to Andrew Witty, global CEO of the world’s second-largest drug maker. GSK was also evaluating potential acquisitions and alliances with Indian drug makers, but will not pay unreasonably high valuations expected by Indian companies.

Stressing the growing share of low-income consumers in GSK’s India sales, the company was working on plans to price its products accordingly. The long-term purpose of the initiative is to make its medicines accessible to all income groups. The strategy will be executed through a combination of alliances with local firms or reduction of prices of selective brands. Among GSK’s popular mass products in India are health drink Horlicks and painkiller Crocin. The company operates through two listed arms in India, GSK Consumer Healthcare Ltd and GSK Pharmaceuticals Ltd.

The pharmaceutical market is growing 15-20% in emerging markets such as India compared with a low single digit in developed countries. This had led to global pharma majors Pfizer, GSK and Sanofi Aventis, which are set to lose patents of their blockbuster drugs, to buy or tie-up with Indian companies to leverage the latter’s low-cost advantage.

crackcrack

Glaxo.Cons. Health Share Price

9696.40 0.00 (0.00%)
15-Apr-2020 18:01 View Price Chart
Peers
Company Name CMP
Varun Beverages 446.00
Nestle 1256.30
Britannia Inds 5654.35
LT Foods 412.05
Hatsun Agro Product 937.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×